Clinical Trial Update: Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Velcade, Trisenox, vitamin C, and melphalan in myeloma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Melphalan (Melphalan)
• Trisenox (arsenic trioxide)
• Velcade (bortezomib)
• Vitamin C (ascorbic acid)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-04-25